Patrick M. Moriarty

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Vera Bittner, Michael Szarek, Philip E. Aylward et al. · Journal of the American College of Cardiology · 2020 · 572 citations · Full text

Medicine, Cardiology, Pharmacology +17

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Patrick M. Moriarty, Paul D. Thompson, Christopher P. Cannon et al. · Journal of clinical lipidology · 2015 · 467 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Ioanna Gouni‐Berthold, Veronica J. Alexander, Qingqing Yang et al. · The Lancet Diabetes & Endocrinology · 2021 · 226 citations

Medicine, Pharmacology, Pharmacotherapy +2

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Eli M. Roth, Patrick M. Moriarty, Jean Bergeron et al. · Atherosclerosis · 2016 · 124 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Lipoprotein(a) Mass Levels Increase Significantly According to <i>APOE</i> Genotype

Patrick M. Moriarty, Stephen A. Varvel, Philip L.S.M. Gordts et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2017 · 89 citations · Full text

Life Sciences, Biochemistry, Biochemical Genetics +16